Influenza Infections and Emergent Viral Infections in Intensive Care Unit

Ben Cantan; Charles-Edouard Luyt; Ignacio Martin-Loeches

doi:10.1055/s-0039-1693497

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2019; 40(04): 488-497
DOI: 10.1055/s-0039-1693497

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Influenza Infections and Emergent Viral Infections in Intensive Care Unit

Ben Cantan

¹Multidisciplinary Intensive Care Research Organization, St James's Hospital, Dublin, Ireland

,

Charles-Edouard Luyt

²Médecine Intensive Réanimation, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Sorbonne University (Paris 6), Paris, France

³INSERM, UMRS 1166-iCAN, Institute of Cardiometabolism and Nutrition, Paris, France

,

Ignacio Martin-Loeches

¹Multidisciplinary Intensive Care Research Organization, St James's Hospital, Dublin, Ireland

⁴Department of Pulmonology, Hospital Clínic de Barcelona, Universitat de Barcelona and IDIBAPS, Barcelona, Spain

⁵Centro de Investigación Biomédica en Red (CIBER), University of Barcelona, Barcelona, Spain

› Author Affiliations

Abstract

Critically ill patients are admitted to an intensive care unit (ICU) for multiple reasons. In this study, we aim to analyze the current evidence and findings associated with influenza and other emergent viral infections, namely, herpes simplex virus type 1 (HSV-1), Epstein-Barr virus (EBV), and cytomegalovirus (CMV).

Among medical conditions, community-acquired respiratory infections are the most frequent reason for ventilatory support in ICUs. Community-acquired pneumonia in a severe form including the need of invasive mechanical ventilation and/or vasopressors is associated with high mortality rates. However, after the pandemic that occurred in 2009 by H1N1 influenza, the number of cases being admitted to ICUs with viral infections is on the rise. Patients in whom an etiology would not have been identified in the past are currently being tested with more sensitive viral molecular diagnostic tools, and patients being admitted to ICUs have more preexisting medical conditions that can predispose to viral infections. Viral infections can trigger the dysregulation of the immune system by inducing a massive cytokine response. This cytokine storm can cause endothelial damage and dysfunction, deregulation of coagulation, and, consequently, alteration of microvascular permeability, tissue edema, and shock. In severe influenza, this vascular hyperpermeability can lead to acute lung injury, multiorgan failure, and encephalopathy. In immunocompetent patients, the most common viral infections are respiratory, and influenza should be considered in patients with severe respiratory failure being admitted to ICU. Seasonality and coinfection are two important features when considering influenza as a pathogen in critically ill patients.

Herpesviridae (HSV, CMV, and EBV) may reactivate in ICU patients, and their reactivation is associated with morbidity/mortality. However, whether a specific treatment may impact on outcome remains to be determined.

Keywords

community-acquired respiratory infections - herpesviridae - intensive care unit

Full Text

References

References
1 Cohen M, Zhang XQ, Senaati HP. , et al. Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase. Virol J 2013; 10: 321
2 WHO. A revision of the system of nomenclature for influenza viruses: a WHO memorandum. Bull World Health Organ 1980; 58 (04) 585-591
3 Petrova VN, Russell CA. The evolution of seasonal influenza viruses. Nat Rev Microbiol 2018; 16 (01) 47-60
4 Ziegler T, Mamahit A, Cox NJ. 65 years of influenza surveillance by a World Health Organization-coordinated global network. Influenza Other Respir Viruses 2018; 12: 558-565
5 Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol Rev 1992; 56 (01) 152-179
6 Jagadesh A, Salam AA, Mudgal PP, Arunkumar G. Influenza virus neuraminidase (NA): a target for antivirals and vaccines. Arch Virol 2016; 161 (08) 2087-2094
7 Taubenberger JK, Morens DM. 1918 Influenza: the mother of all pandemics. Emerg Infect Dis 2006; 12 (01) 15-22
8 Patterson KD, Pyle GF. The geography and mortality of the 1918 influenza pandemic. Bull Hist Med 1991; 65 (01) 4-21
9 Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 “Spanish” influenza pandemic. Bull Hist Med 2002; 76 (01) 105-115
10 Bouvier NM, Palese P. The biology of influenza viruses. Vaccine 2008; 26 (Suppl. 04) D49-D53
11 Gambotto A, Barratt-Boyes SM, de Jong MD, Neumann G, Kawaoka Y. Human infection with highly pathogenic H5N1 influenza virus. Lancet 2008; 371 (9622): 1464-1475
12 Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348 (02) 138-150
13 Brown MA, Jones WK. NF-kappaB action in sepsis: the innate immune system and the heart. Front Biosci 2004; 9: 1201-1217
14 Russell JA. Management of sepsis. N Engl J Med 2006; 355 (16) 1699-1713
15 Florescu DF, Kalil AC. Cytomegalovirus infections in non-immunocompromised and immunocompromised patients in the intensive care unit. Infect Disord Drug Targets 2011; 11 (04) 354-364
16 Florescu DF, Kalil AC. The complex link between influenza and severe sepsis. Virulence 2014; 5 (01) 137-142
17 Steinberg BE, Goldenberg NM, Lee WL. Do viral infections mimic bacterial sepsis? The role of microvascular permeability: a review of mechanisms and methods. Antiviral Res 2012; 93 (01) 2-15
18 de Jong MD, Simmons CP, Thanh TT. , et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006; 12 (10) 1203-1207
19 Peiris M. Pathogenesis of avian flu H5N1 and SARS. Novartis Found Symp 2006; 279: 56-60 , discussion 60–65, 216–219
20 Uiprasertkul M, Puthavathana P, Sangsiriwut K. , et al. Influenza A H5N1 replication sites in humans. Emerg Infect Dis 2005; 11 (07) 1036-1041
21 Taubenberger JK, Morens DM. The pathology of influenza virus infections. Annu Rev Pathol 2008; 3: 499-522
22 Kaji M, Watanabe A, Aizawa H. Differences in clinical features between influenza A H1N1, A H3N2, and B in adult patients. Respirology 2003; 8 (02) 231-233
23 Hong KW, Cheong HJ, Song JY, Noh JY, Yang TU, Kim WJ. Clinical manifestations of influenza A and B in children and adults at a tertiary hospital in Korea during the 2011-2012 season. Jpn J Infect Dis 2015; 68 (01) 20-26
24 Wie SH, So BH, Song JY. , et al. A comparison of the clinical and epidemiological characteristics of adult patients with laboratory-confirmed influenza A or B during the 2011-2012 influenza season in Korea: a multi-center study. PLoS One 2013; 8 (05) e62685
25 Garg S, Jain S, Dawood FS. , et al. Pneumonia among adults hospitalized with laboratory-confirmed seasonal influenza virus infection-United States, 2005-2008. BMC Infect Dis 2015; 15: 369
26 Coleman BL, Fadel SA, Fitzpatrick T, Thomas SM. Risk factors for serious outcomes associated with influenza illness in high- versus low- and middle-income countries: systematic literature review and meta-analysis. Influenza Other Respir Viruses 2018; 12 (01) 22-29
27 Johnstone J, Majumdar SR, Fox JD, Marrie TJ. Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation. Chest 2008; 134 (06) 1141-1148
28 Pavia AT. What is the role of respiratory viruses in community-acquired pneumonia?: what is the best therapy for influenza and other viral causes of community-acquired pneumonia?. Infect Dis Clin North Am 2013; 27 (01) 157-175
29 Jain S, Self WH, Wunderink RG. , et al; CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 2015; 373 (05) 415-427
30 Alimi Y, Lim WS, Lansbury L, Leonardi-Bee J, Nguyen-Van-Tam JS. Systematic review of respiratory viral pathogens identified in adults with community-acquired pneumonia in Europe. J Clin Virol 2017; 95: 26-35
31 Wu X, Wang Q, Wang M. , et al. Incidence of respiratory viral infections detected by PCR and real-time PCR in adult patients with community-acquired pneumonia: a meta-analysis. Respiration 2015; 89 (04) 343-352
32 Walter ND, Taylor TH, Shay DK. , et al; Active Bacterial Core Surveillance Team. Influenza circulation and the burden of invasive pneumococcal pneumonia during a non-pandemic period in the United States. Clin Infect Dis 2010; 50 (02) 175-183
33 Grabowska K, Högberg L, Penttinen P, Svensson A, Ekdahl K. Occurrence of invasive pneumococcal disease and number of excess cases due to influenza. BMC Infect Dis 2006; 6: 58
34 Klein EY, Monteforte B, Gupta A. , et al. The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. Influenza Other Respir Viruses 2016; 10 (05) 394-403
35 Martin-Loeches I, , J Schultz M, Vincent JL. , et al. Increased incidence of co-infection in critically ill patients with influenza. Intensive Care Med 2017; 43 (01) 48-58
36 Martin-Loeches I, Lemiale V, Geoghegan P. , et al; Efraim investigators and the Nine-I study group. Influenza and associated co-infections in critically ill immunosuppressed patients. Crit Care 2019; 23 (01) 152
37 Martín-Loeches I, Sanchez-Corral A, Diaz E. , et al; H1N1 SEMICYUC Working Group. Community-acquired respiratory coinfection in critically ill patients with pandemic 2009 influenza A(H1N1) virus. Chest 2011; 139 (03) 555-562
38 Schauwvlieghe AFAD, Rijnders BJA, Philips N. , et al; Dutch-Belgian Mycosis study group. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med 2018; 6 (10) 782-792
39 Muthuri SG, Venkatesan S, Myles PR. , et al; PRIDE Consortium Investigators. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis. Influenza Other Respir Viruses 2016; 10 (03) 192-204
40 Rodríguez A, Díaz E, Martín-Loeches I. , et al; H1N1 SEMICYUC Working Group. Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A. J Antimicrob Chemother 2011; 66 (05) 1140-1149
41 Lytras T, Mouratidou E, Andreopoulou A, Bonovas S, Tsiodras S. Effect of early oseltamivir treatment on mortality in critically ill patients with different types of influenza: a multi-season cohort study. Clin Infect Dis 2019 (e-pub ahead of print). Doi:10.1093/cid/ciz101
42 Ariano RE, Sitar DS, Zelenitsky SA. , et al. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ 2010; 182 (04) 357-363
43 Network SEAIDCR. ; South East Asia Infectious Disease Clinical Research Network. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. BMJ 2013; 346: f3039
44 World Health Organization. WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and Other Influenza Viruses. https://www.who.int/csr/resources/publications/swineflu/h1n1_guidelines_pharmaceutical_mngt_part2.pdf . Accesed 15 June 2019
45 Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM. ; Centers for Disease Control and Prevention (CDC). Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60 (01) 1-24
46 Yoo JW, Choi SH, Huh JW, Lim CM, Koh Y, Hong SB. Peramivir is as effective as oral oseltamivir in the treatment of severe seasonal influenza. J Med Virol 2015; 87 (10) 1649-1655
47 Kong LK, Zhou BP. Successful treatment of avian influenza with convalescent plasma. Hong Kong Med J 2006; 12 (06) 489
48 Yu H, Gao Z, Feng Z. , et al. Clinical characteristics of 26 human cases of highly pathogenic avian influenza A (H5N1) virus infection in China. PLoS One 2008; 3 (08) e2985
49 Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007; 357 (14) 1450-1451
50 Hung IF, To KK, Lee CK. , et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011; 52 (04) 447-456
51 Hui DS, Lee N, Chan PK, Beigel JH. The role of adjuvant immunomodulatory agents for treatment of severe influenza. Antiviral Res 2018; 150: 202-216
52 Martín-Loeches I, Bermejo-Martin JF, Vallés J. , et al; SEMICYUC/REIPI/CIBERES H1N1 Working Group. Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia. Intensive Care Med 2013; 39 (04) 693-702
53 Lansbury L, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev 2019; 2: CD010406
54 Zhang Y, Sun W, Svendsen ER. , et al. Do corticosteroids reduce the mortality of influenza A (H1N1) infection? A meta-analysis. Crit Care 2015; 19: 46
55 Yang JW, Fan LC, Miao XY. , et al. Corticosteroids for the treatment of human infection with influenza virus: a systematic review and meta-analysis. Clin Microbiol Infect 2015; 21 (10) 956-963
56 Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam JS, Lim WS. Effect of corticosteroid therapy on influenza-related mortality: a systematic review and meta-analysis. J Infect Dis 2015; 212 (02) 183-194
57 Sukhal S, Sethi J, Ganesh M, Villablanca PA, Malhotra AK, Ramakrishna H. Extracorporeal membrane oxygenation in severe influenza infection with respiratory failure: a systematic review and meta-analysis. Ann Card Anaesth 2017; 20 (01) 14-21
58 Estabragh ZR, Mamas MA. The cardiovascular manifestations of influenza: a systematic review. Int J Cardiol 2013; 167 (06) 2397-2403
59 Onitsuka H, Imamura T, Miyamoto N. , et al. Clinical manifestations of influenza a myocarditis during the influenza epidemic of winter 1998-1999. J Cardiol 2001; 37 (06) 315-323
60 Sellers SA, Hagan RS, Hayden FG, Fischer II WA. The hidden burden of influenza: a review of the extra-pulmonary complications of influenza infection. Influenza Other Respir Viruses 2017; 11 (05) 372-393
61 Brown SM, Pittman J, Miller Iii RR. , et al. Right and left heart failure in severe H1N1 influenza A infection. Eur Respir J 2011; 37 (01) 112-118
62 Warren-Gash C, Bhaskaran K, Hayward A. , et al. Circulating influenza virus, climatic factors, and acute myocardial infarction: a time series study in England and Wales and Hong Kong. J Infect Dis 2011; 203 (12) 1710-1718
63 Kwok CS, Aslam S, Kontopantelis E. , et al. Influenza, influenza-like symptoms and their association with cardiovascular risks: a systematic review and meta-analysis of observational studies. Int J Clin Pract 2015; 69 (09) 928-937
64 Ciszewski A, Bilinska ZT, Brydak LB. , et al. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. Eur Heart J 2008; 29 (11) 1350-1358
65 Siriwardena AN, Gwini SM, Coupland CA. Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: matched case-control study. CMAJ 2010; 182 (15) 1617-1623
66 Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis 2010; 10 (02) 83-92
67 Meijer WJ, Linn FHH, Wensing AMJ. , et al. Acute influenza virus-associated encephalitis and encephalopathy in adults: a challenging diagnosis. JMM Case Rep 2016; 3 (06) e005076
68 Tam CC, O'Brien SJ, Petersen I, Islam A, Hayward A, Rodrigues LC. Guillain-Barré syndrome and preceding infection with campylobacter, influenza and Epstein-Barr virus in the general practice research database. PLoS One 2007; 2 (04) e344
69 Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database. Am J Epidemiol 2009; 169 (03) 382-388
70 Borgatta B, Pérez M, Rello J. , et al; pH1N1 GTEI/SEMICYUC. Elevation of creatine kinase is associated with worse outcomes in 2009 pH1N1 influenza A infection. Intensive Care Med 2012; 38 (07) 1152-1161
71 Wong JY, Kelly H, Cheung CM. , et al. Hospitalization fatality risk of influenza A(H1N1)pdm09: a systematic review and meta-analysis. Am J Epidemiol 2015; 182 (04) 294-301
72 Khandaker G, Dierig A, Rashid H, King C, Heron L, Booy R. Systematic review of clinical and epidemiological features of the pandemic influenza A (H1N1) 2009. Influenza Other Respir Viruses 2011; 5 (03) 148-156
73 Duggal A, Pinto R, Rubenfeld G, Fowler RA. Global variability in reported mortality for critical illness during the 2009-10 influenza A(H1N1) pandemic: a systematic review and meta-regression to guide reporting of outcomes during disease outbreaks. PLoS One 2016; 11 (05) e0155044
74 Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013; 13 (03) 260-268
75 Bruynseels P, Jorens PG, Demey HE. , et al. Herpes simplex virus in the respiratory tract of critical care patients: a prospective study. Lancet 2003; 362 (9395): 1536-1541
76 Luyt CE, Combes A, Deback C. , et al. Herpes simplex virus lung infection in patients undergoing prolonged mechanical ventilation. Am J Respir Crit Care Med 2007; 175 (09) 935-942
77 Ong GM, Lowry K, Mahajan S. , et al. Herpes simplex type 1 shedding is associated with reduced hospital survival in patients receiving assisted ventilation in a tertiary referral intensive care unit. J Med Virol 2004; 72 (01) 121-125
78 Linssen CF, Jacobs JA, Stelma FF. , et al. Herpes simplex virus load in bronchoalveolar lavage fluid is related to poor outcome in critically ill patients. Intensive Care Med 2008; 34 (12) 2202-2209
79 Costa C, Sidoti F, Saldan A. , et al. Clinical impact of HSV-1 detection in the lower respiratory tract from hospitalized adult patients. Clin Microbiol Infect 2012; 18 (08) E305-E307
80 De Vos N, Van Hoovels L, Vankeerberghen A. , et al. Monitoring of herpes simplex virus in the lower respiratory tract of critically ill patients using real-time PCR: a prospective study. Clin Microbiol Infect 2009; 15 (04) 358-363
81 Luyt CE, Combes A, Nieszkowska A, Trouillet JL, Chastre J. Viral infections in the ICU. Curr Opin Crit Care 2008; 14 (05) 605-608
82 Coisel Y, Bousbia S, Forel JM. , et al. Cytomegalovirus and herpes simplex virus effect on the prognosis of mechanically ventilated patients suspected to have ventilator-associated pneumonia. PLoS One 2012; 7 (12) e51340
83 Tuxen DV, Wilson JW, Cade JF. Prevention of lower respiratory herpes simplex virus infection with acyclovir in patients with the adult respiratory distress syndrome. Am Rev Respir Dis 1987; 136 (02) 402-405
84 Traen S, Bochanen N, Ieven M. , et al. Is acyclovir effective among critically ill patients with herpes simplex in the respiratory tract?. J Clin Virol 2014; 60 (03) 215-221
85 Jaber S, Chanques G, Borry J. , et al. Cytomegalovirus infection in critically ill patients: associated factors and consequences. Chest 2005; 127 (01) 233-241
86 Limaye AP, Kirby KA, Rubenfeld GD. , et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 2008; 300 (04) 413-422
87 Chiche L, Forel JM, Roch A. , et al. Active cytomegalovirus infection is common in mechanically ventilated medical intensive care unit patients. Crit Care Med 2009; 37 (06) 1850-1857
88 Limaye AP, Stapleton RD, Peng L. , et al. Effect of ganciclovir on IL-6 levels among cytomegalovirus-seropositive adults with critical illness: a randomized clinical trial. JAMA 2017; 318 (08) 731-740
89 Papazian L, Fraisse A, Garbe L. , et al. Cytomegalovirus. An unexpected cause of ventilator-associated pneumonia. Anesthesiology 1996; 84 (02) 280-287
90 Papazian L, Doddoli C, Chetaille B. , et al. A contributive result of open-lung biopsy improves survival in acute respiratory distress syndrome patients. Crit Care Med 2007; 35 (03) 755-762
91 Li X, Huang Y, Xu Z. , et al. Cytomegalovirus infection and outcome in immunocompetent patients in the intensive care unit: a systematic review and meta-analysis. BMC Infect Dis 2018; 18 (01) 289
92 Cowley NJ, Owen A, Shiels SC. , et al. Safety and efficacy of antiviral therapy for prevention of cytomegalovirus reactivation in immunocompetent critically ill patients: a randomized clinical trial. JAMA Intern Med 2017; 177 (06) 774-783
93 Tachikawa R, Tomii K, Seo R. , et al. Detection of herpes viruses by multiplex and real-time polymerase chain reaction in bronchoalveolar lavage fluid of patients with acute lung injury or acute respiratory distress syndrome. Respiration 2014; 87 (04) 279-286
94 Libert N, Bigaillon C, Chargari C. , et al. Epstein-Barr virus reactivation in critically ill immunocompetent patients. Biomed J 2015; 38 (01) 70-76
95 Ong DSY, Bonten MJM, Spitoni C. , et al; Molecular Diagnosis and Risk Stratification of Sepsis Consortium. Epidemiology of multiple herpes viremia in previously immunocompetent patients with septic shock. Clin Infect Dis 2017; 64 (09) 1204-1210
96 Forel JM, Martin-Loeches I, Luyt CE. Treating HSV and CMV reactivations in critically ill patients who are not immunocompromised: pro. Intensive Care Med 2014; 40 (12) 1945-1949
97 Papazian L, Hraiech S, Lehingue S. , et al. Cytomegalovirus reactivation in ICU patients. Intensive Care Med 2016; 42 (01) 28-37